Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2MILAN and NEW YORK, Oct. 02, 2024 (GLOBE…
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a…
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic…
SANTA CRUZ, Calif., Oct. 1, 2024 /PRNewswire/ -- Fullpower-AI®, in collaboration with Stanford University and UCSF, is proud to announce…
Seasoned Clinical Research Leader to Drive Innovative Solutions for Streamlining Study Start-Ups and Supporting Research SitesMADISON, WI / ACCESSWIRE /…
FORT MYERS, Fla., Oct. 1, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome board-certified medical…
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year…
- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study…
WASHINGTON, DC / ACCESSWIRE / October 1, 2024 / Boosting research investment into the health and wellbeing of adults with…
The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP…